TET2 and myocardial infarction: These observations promoted the hypothesis that IL-1β neutralization would lead to a greater reduction in MACEs, and this was indeed the case in a subgroup analysis of the CANTOS trial that included patients with a history of myocardial infarction, elevated high-sensitivity C-reactive protein, and CHIP variant TET2 clones [100].